Nancy Mize at Pacific BioDevelopment: PharmacoGenomics

Expertise

• Pharmacogenomics/proteomics Study Design/ Strategic Planning.
• Selection and ranking of patient populations for trials based on statistical analyses.
• Criteria for use of Pharmacogenomic/proteomic data for varying dosing regimens and/or rank order of patient populations.
• Review of FDA guidelines on whether a test is defined as clinical (diagnostic) or non-clinical (research).
• Statistical analyses and review of Pharmacogenomic/proteomic assay results.

Career Highlights

• 2002 to Present:  Consultant to the Bio-Pharmaceutical Industry.
• Consultant for several biotechnology and pharmaceutical companies.
• Assisted with preclinical and clinical development strategy for new molecules and new transdermal delivery systems.
• Developed plans for preclinical studies and tox studies.
• Statistical Analyses of microarray and proteinchip assays.
• Coordination of oncology therapy with pharmacogenomics tests.
• More than 25 U.S. and European patent applications.
• Fifteen years experience in genomics, proteomics, and drug development.

1999-2002 Director Protein Bioinformatics, Genomics, Hyseq
1997-1999 Application Scientist, Proteomics, Ciphergen
1992-1997 Research Scientist, Alza (Johnson & Johnson)
1991-1992 Genentech, Molecular Biology Department
1988-1991 European Molecular Biology Laboratory, GenBank

Education

• Ph.D., Physiology, University of California, San Francisco
• B.S., Biology, Bioenergetics, University of California, Berkeley